April 17, 2021


Advances in world technology

Pulse Biosciences Updates on CellFX Method Regulatory and Scientific Study Progress

HAYWARD, Calif.–(Organization WIRE)–Jan 12, 2021– Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”),...

HAYWARD, Calif.–(Organization WIRE)–Jan 12, 2021–

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine corporation progressing Nano-Pulse Stimulation™ (NPS™) engineering, nowadays declared CellFX ® Program regulatory development updates.

New CellFX Program Highlights

  • Acquired notification from the Meals and Drug Administration (Fda) that the Company’s 510(k) submission for a standard dermatology indicator for the CellFX Program has state-of-the-art from Substantive Review to Interactive Assessment.
  • Accomplished all therapies in the Company’s beforehand declared pivotal comparison study to examine the remedy of sebaceous hyperplasia (SH) working with the CellFX Procedure, with the planned certain indicator 510(k) submission as early as the finish of the to start with quarter of 2021.
  • Received Food and drug administration Investigational Unit Exemption (IDE) approval of a pivotal comparison review to examine the treatment of cutaneous non-genital warts making use of the CellFX Method, with enrollment expected to begin by the stop of the initial quarter of 2021.
  • Ongoing critique by the Notified Entire body of the CellFX System for CE mark acceptance and Health and fitness Canada for Health care Machine License continues to be on track.

“We are extremely delighted with the development our crew made throughout a hard 2020 in advancing the CellFX Technique and in interactions with regulatory authorities in the US, European Union and Canada,” claimed Darrin Uecker, President and Chief Govt Officer of Pulse Biosciences. “We go on to operate with the regulatory authorities in each and every of these geographies and take pleasure in the collaborative and well timed interactions we have experienced all through these opinions.”

About Pulse Biosciences ®

Pulse Biosciences is a novel bioelectric drugs business fully commited to health and fitness innovation that has the possible to boost the excellent of existence for sufferers. If cleared, the CellFX ® Program is the to start with commercial product or service to harness the unique advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) know-how, this sort of as the capacity to non-thermally very clear cells when sparing non-mobile tissue, to deal with a range of applications for which an exceptional alternative remains unfulfilled. Nano-Pulse Stimulation technologies provides nano-2nd pulses of electrical electrical power. Topic to regulatory approval, the initial industrial use of the CellFX System is to deal with a selection of dermatologic ailments that share significant demand from customers amongst patients and practitioners for enhanced dermatologic outcomes. Built as a multi-application platform, the CellFX Technique delivers customer price with a utilization-primarily based revenue product. To master more, be sure to take a look at pulsebiosciences.com.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are amongst the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Warning: Pulse Biosciences’ CellFX Program and Nano-Pulse Stimulation technologies are deemed for investigational use only.

Forward-Wanting Statements

All statements in this push launch that are not historical are ahead-seeking statements, which includes, among the other issues, statements relating to Pulse Biosciences’ expectations regarding regulatory clearance and the timing of Food and drug administration, notified overall body, Overall health Canada and other regulatory human body filings or approvals, and the means of the Corporation to efficiently entire a 510(k) submission for the CellFX Process or for any precise indications, the ability of the Company to prepare and give facts to Fda, EU, Canadian and other regulatory bodies, NPS technologies which include the performance of such technological know-how and the performance of connected medical research in predicting results resulting from the use of NPS technologies, the CellFX Program such as the rewards of the CellFX Program and commercialization of the CellFX Method, recent and prepared upcoming medical studies and the potential of the Organization to execute this kind of reports and effects of any such scientific studies, other matters linked to its pipeline of solution candidates, the Company’s marketplace prospect and commercialization options, together with the sector for the treatment of specified lesions, long run money functionality, and other future occasions. These statements are not historic facts but rather are centered on Pulse Biosciences’ existing anticipations, estimates, and projections concerning Pulse Biosciences’ business enterprise, functions and other similar or similar factors. Words and phrases these types of as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other comparable or associated expressions are applied to establish these ahead-searching statements, despite the fact that not all ahead-searching statements have these text. You need to not area undue reliance on forward-on the lookout statements for the reason that they include identified and unknown risks, uncertainties, and assumptions that are hard or extremely hard to predict and, in some conditions, outside of Pulse Biosciences’ command. Genuine success may well vary materially from these in the ahead-looking statements as a result of a number of variables, like all those described in Pulse Biosciences’ filings with the Securities and Exchange Fee. Pulse Biosciences undertakes no obligation to revise or update information and facts in this release to mirror gatherings or circumstances in the foreseeable future, even if new info becomes out there.

See resource edition on businesswire.com:https://www.businesswire.com/news/residence/20210112005399/en/

Contact: Investors:

Pulse Biosciences

Sandra Gardiner, EVP and CFO


[email protected]


Gilmartin Group

Philip Journey Taylor


[email protected]:

Tosk Communications

Nadine D. Tosk


[email protected]

[email protected]


Industry Search term: Fda Operation Professional medical Units Well being Medical TRIALS

Supply: Pulse Biosciences, Inc.

Copyright Company Wire 2021.

PUB: 01/12/2021 07:00 AM/DISC: 01/12/2021 07:01 AM